{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T20:51:29Z","timestamp":1790196689967,"version":"4.1.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2018,3,2]],"date-time":"2018-03-02T00:00:00Z","timestamp":1519948800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2018,3,2]],"date-time":"2018-03-02T00:00:00Z","timestamp":1519948800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"The work was conducted in the context of a European Commission sponsored joint action, Strengthening Collaboration for Operating Pharmacovigilance in Europe (SCOPE).","award":["The survey was made possible through a tendered sub contract ITT-1301"],"award-info":[{"award-number":["The survey was made possible through a tendered sub contract ITT-1301"]}]},{"name":"The work was conducted in the context of a European Commission sponsored joint action, Strengthening Collaboration for Operating Pharmacovigilance in Europe (SCOPE).","award":["ECM-2294."],"award-info":[{"award-number":["ECM-2294."]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Saf"],"published-print":{"date-parts":[[2018,7]]},"DOI":"10.1007\/s40264-018-0643-5","type":"journal-article","created":{"date-parts":[[2018,3,2]],"date-time":"2018-03-02T08:34:00Z","timestamp":1519979640000},"page":"713-724","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Safety Communication Tools and Healthcare Professionals\u2019 Awareness of Specific Drug Safety Issues in Europe: A Survey Study"],"prefix":"10.1007","volume":"41","author":[{"name":"on behalf of SCOPE work package 6","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6090-2434","authenticated-orcid":false,"given":"Sieta T.","family":"de Vries","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maartje J. M.","family":"van der Sar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Marie","family":"Coleman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yvette","family":"Escudero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfonso","family":"Rodr\u00edguez Pascual","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel-\u00c1ngel","family":"Maci\u00e1 Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amelia","family":"Cupelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilaria","family":"Baldelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivana","family":"\u0160ipi\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriana","family":"Andri\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Line","family":"Michan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petra","family":"Denig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter G. M.","family":"Mol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,3,2]]},"reference":[{"key":"643_CR1","unstructured":"European Medicines Agency. European Medicines Agency recommends suspension of Avandia, Avandamet and Avaglim. [Internet]. \n                    http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Press_release\/2010\/09\/WC500096996.pdf\n                    \n                  . Accessed 23 Jan 2018."},{"key":"643_CR2","unstructured":"European Medicines Agency. European Medicines Agency recommends suspension of marketing authorisations for sibutramine. [Internet]. \n                    http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Press_release\/2010\/01\/WC500069995.pdf\n                    \n                  . Accessed 23 Jan 2018."},{"issue":"6","key":"643_CR3","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1097\/MLR.0b013e318245a160","volume":"50","author":"SB Dusetzina","year":"2012","unstructured":"Dusetzina SB, Higashi AS, Dorsey ER, Conti R, Huskamp HA, Zhu S, et al. Impact of FDA drug risk communications on health care utilization and health behaviors: a systematic review. Med Care. 2012;50(6):466\u201378.","journal-title":"Med Care"},{"issue":"5","key":"643_CR4","doi-asserted-by":"publisher","first-page":"373","DOI":"10.2165\/11599100-000000000-00000","volume":"35","author":"S Piening","year":"2012","unstructured":"Piening S, Haaijer-Ruskamp FM, de Vries JT, van der Elst ME, de Graeff PA, Straus SM, et al. Impact of safety-related regulatory action on clinical practice: a systematic review. Drug Saf. 2012;35(5):373\u201385.","journal-title":"Drug Saf"},{"issue":"5","key":"643_CR5","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1038\/clpt.2011.308","volume":"91","author":"S Piening","year":"2012","unstructured":"Piening S, Reber KC, Wieringa JE, Straus SM, de Graeff PA, Haaijer-Ruskamp FM, et al. Impact of safety-related regulatory action on drug use in ambulatory care in the Netherlands. Clin Pharmacol Ther. 2012;91(5):838\u201345.","journal-title":"Clin Pharmacol Ther"},{"issue":"11","key":"643_CR6","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1007\/BF03261992","volume":"35","author":"S Piening","year":"2012","unstructured":"Piening S, Haaijer-Ruskamp FM, de Graeff PA, Straus SM, Mol PG. Healthcare professionals\u2019 self-reported experiences and preferences related to direct healthcare professional communications: a survey conducted in the Netherlands. Drug Saf. 2012;35(11):1061\u201372.","journal-title":"Drug Saf"},{"key":"643_CR7","unstructured":"European Medicines Agency. Guideline on good pharmacovigilance practices (GVP) Module XV \u2013 Safety communication. [Internet]. \n                    http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2013\/01\/WC500137666.pdf\n                    \n                  . Accessed 23 Jan 2018."},{"key":"643_CR8","doi-asserted-by":"crossref","unstructured":"De Vries ST, van der Sar MJM, Cupelli A, Baldelli I, Coleman AM, Montero D, Andri\u0107 A, Wennberg A, Ahlqvist-Rastad J, Denig P, Mol PGM, on behalf of SCOPE Work Package 6. Communication on safety of medicines in Europe: current practices and general practitioners\u2019 awareness and preferences. Drug Saf 2017;40(8):729\u201342.","DOI":"10.1007\/s40264-017-0535-0"},{"issue":"12","key":"643_CR9","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1056\/NEJMoa1406430","volume":"371","author":"K Fox","year":"2014","unstructured":"Fox K, Ford I, Steg PG, Tardif JC, Tendera M, Ferrari R, et al. Ivabradine in stable coronary artery disease without clinical heart failure. N Engl J Med. 2014;371(12):1091\u20139.","journal-title":"N Engl J Med"},{"issue":"4","key":"643_CR10","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1111\/j.1539-6924.2011.01647.x","volume":"32","author":"MK Lindell","year":"2012","unstructured":"Lindell MK, Perry RW. The protective action decision model: theoretical modifications and additional evidence. Risk Anal. 2012;32(4):616\u201332.","journal-title":"Risk Anal"},{"issue":"1","key":"643_CR11","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s40264-013-0126-7","volume":"37","author":"AK Banerjee","year":"2014","unstructured":"Banerjee AK, Zomerdijk IM, Wooder S, Ingate S, Mayall SJ. Post-approval evaluation of effectiveness of risk minimisation: methods, challenges and interpretation. Drug Saf. 2014;37(1):33\u201342.","journal-title":"Drug Saf"},{"key":"643_CR12","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.13469","author":"T Goedecke","year":"2017","unstructured":"Goedecke T, Morales DR, Pacurariu A, Kurz X. Measuring the impact of medicines regulatory interventions\u2014systematic review and methodological considerations. Br J Clin Pharmacol. 2017. \n                    https:\/\/doi.org\/10.1111\/bcp.13469\n                    \n                  .","journal-title":"Br J Clin Pharmacol"},{"key":"643_CR13","doi-asserted-by":"publisher","first-page":"211","DOI":"10.2147\/JMDH.S104807","volume":"9","author":"A Althubaiti","year":"2016","unstructured":"Althubaiti A. Information bias in health research: definition, pitfalls, and adjustment methods. J Multidiscip Healthc. 2016;9:211\u20137.","journal-title":"J Multidiscip Healthc"},{"issue":"3","key":"643_CR14","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1007\/s11575-011-0111-2","volume":"52","author":"A Harzing","year":"2012","unstructured":"Harzing A, Brown M, K\u00f6ster K, Zhao S. Response style differences in cross-national research. Manage Int Rev. 2012;52(3):341\u201363.","journal-title":"Manage Int Rev"},{"key":"643_CR15","unstructured":"Tellis GJ, Chandrasekaran D. Does culture matter? Assessing response biases in cross-national survey research. International Journal of Research in Marketing 2010. [Internet]. \n                    https:\/\/ssrn.com\/abstract=1659911\n                    \n                  . Accessed 23 Jan 2018."}],"updated-by":[{"DOI":"10.1007\/s40264-020-00972-x","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2020,6,30]],"date-time":"2020-06-30T00:00:00Z","timestamp":1593475200000}}],"container-title":["Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40264-018-0643-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-018-0643-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-018-0643-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,30]],"date-time":"2020-06-30T10:26:47Z","timestamp":1593512807000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40264-018-0643-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3,2]]},"references-count":15,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2018,7]]}},"alternative-id":["643"],"URL":"https:\/\/doi.org\/10.1007\/s40264-018-0643-5","relation":{},"ISSN":["0114-5916","1179-1942"],"issn-type":[{"value":"0114-5916","type":"print"},{"value":"1179-1942","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,3,2]]},"assertion":[{"value":"2 March 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2020","order":2,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":3,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"In the original publication of the article, the headings of columns 3 and 4 in the data table.","order":4,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Ethical approval was not considered necessary for this study because of the nature of the study, in which healthcare professionals were asked to complete a survey about safety communication strategies. Participants were assured that all sensitive data would be kept confidential.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The work was conducted in the context of a European Commission sponsored joint action, Strengthening Collaboration for Operating Pharmacovigilance in Europe (SCOPE). Any opinions, conclusions and proposals in the text are those of the authors and do not necessarily represent the views of the European Commission or national competent authorities. The survey was made possible through a tendered subcontract ITT-1301, ECM-2294.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Sieta T. de Vries, Maartje J.M. van der Sar, Anna Marie Coleman, Yvette Escudero, Alfonso Rodr\u00edguez Pascual, Miguel-\u00c1ngel Maci\u00e1 Mart\u00ednez, Amelia Cupelli, Ilaria Baldelli, Ivana \u0160ipi\u0107, Adriana Andri\u0107, Line Michan, and Petra Denig have no conflicts of interest that are directly relevant to the content of this study. Peter G.M. Mol is an employee of the Dutch Medicines Evaluation Board.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}